Welcome to the international HTA database

Showing [24603 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2011	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab SC (Herceptin SC) for breast cancer, early or metastatic, HER2 positive - monotherapy or combination therapy, including neo-adjuvant and adjuvant use
2020	Agency for Care Effectiveness (ACE)	Trastuzumab for treating HER2-positive breast and gastric cancers
2009	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal
2010	National Institute for Health and Care Excellence (NICE)	Trastuzumab for the treatment of HER2-positive metastatic gastric cancer. NICE technology appraisal guidance 208
2011	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2006	Quality Improvement Scotland (NHS QIS )	Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
2005	Institute for Clinical Effectiveness and Health Policy (IECS)	Trastuzumab for breast cancer treatment
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab emtansine in combination with pertuzumab for HER2-positive metastatic breast cancer – first line
2017	National Institute for Health and Care Excellence (NICE)	Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. NICE technology appraisal guidance 458
2020	National Institute for Health and Care Excellence (NICE)	Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. NICE technology appraisal guidance 632
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Trastuzumab emtansine (KadcylaTM) for previously treated patients with HER2-positive advanced/metastatic breast cancer
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab emtansine (Kadcyla) for patients with HER2 positive locally advanced or metastatic relapsed gastric cancers
2025	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal). NICE technology appraisal guidance 1112
2023	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal). NICE technology appraisal guidance 879
2021	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 704
2023	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments. NICE technology appraisal guidance 862
2023	Agency for Care Effectiveness (ACE)	Trastuzumab deruxtecan for treating HER2-positive advanced gastric cancer after two or more therapies
2024	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 976
2024	National Institute for Health and Care Excellence (NICE)	Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy. NICE technology appraisal guidance 992
2023	Agency for Care Effectiveness (ACE)	Trastuzumab deruxtecan for previously treated HER2-positive metastatic breast cancer
2024	Agency for Care Effectiveness (ACE)	Trastuzumab deruxtecan for HER2-low unresectable and or metastatic breast cancer after at least one prior line of chemotherapy
2005	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review
2003	ECRI	Trastuzumab [Herceptin (R)] for the treatment of breast cancer
2012	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion
2012	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Trastuzumab (Herceptin®)
2006	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) in combination with aromatase inhibitors for stage IV - metastatic breast cancer: horizon scanning technology briefing
2010	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Trastuzumab (Herceptin) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer
2007	HAYES, Inc.	Trastuzumab (Herceptin) for metastatic cancer
2001	The Swedish Council on Health Technology Assessment (SBU)	Trastuzumab (Herceptin) for metastasized breast cancer - early assessment briefs (Alert)
2010	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer - neoadjuvant treatment
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) for HER2 positive early breast cancer – two year regimen
2007	HAYES, Inc.	Trastuzumab (Herceptin) for early breast cancer
2007	NIHR Horizon Scanning Centre (NIHR HSC)	Trastuzumab (Herceptin) for advanced gastric cancer
2004	HAYES, Inc.	Trastuzumab (Herceptin (R)) for breast cancer
2016	NIHR Health Technology Assessment programme	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
2023	National Institute for Health and Care Excellence (NICE)	Transvenous obliteration for gastric varices. NICE interventional procedures guidance 751
2011	HAYES, Inc.	Transvaginal ultrasound for measurement of cervical length to predict preterm birth
2017	National Institute for Health and Care Excellence (NICE)	Transvaginal mesh repair of anterior or posterior vaginal wall prolapse. NICE interventional procedures guidance 599
2021	National Institute for Health and Care Excellence (NICE)	Transvaginal laser therapy for urogenital atrophy. NICE interventional procedures guidance 697
2021	National Institute for Health and Care Excellence (NICE)	Transvaginal laser therapy for stress urinary incontinence. NICE interventional procedures guidance 696
2023	National Institute for Health and Care Excellence (NICE)	Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 770
2018	National Institute for Health and Care Excellence (NICE)	Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 625
2007	HAYES, Inc.	Transurethral radiofrequency micro-remodeling using the Renessa system (Novasys Medical Inc.) for female stress urinary incontinence
2010	HAYES, Inc.	Transurethral Radiofrequency Micro-Remodeling Using the Renessa System (Novasys Medical Inc.) for Female Stress Urinary Incontinence
2001	HAYES, Inc.	Transurethral needle ablation therapy
2001	ECRI	Transurethral needle ablation [TUNA (R)] for benign prostatic hyperplasia
2005	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Transurethral needle ablation (TUNA) in the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
2002	Medical Services Advisory Committee (MSAC)	TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia
2000	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia
2000	HAYES, Inc.	Transurethral microwave thermotherapy
2007	HAYES, Inc.	Transurethral microwave thermotherapy
2019	National Institute for Health and Care Excellence (NICE)	Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer. NICE interventional procedures guidance 656
2012	Medical Services Advisory Committee (MSAC)	Transurethral injection of botulinum toxin into the ladder wall for urinary incontinence due to neurogenic detrusor overactivity
2003	National Institute for Health and Care Excellence (NICE)	Transurethral electrovaporisation of the prostate. NICE interventional procedures guidance 14
1994	Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS)	Transurethral diathermy for benign prostatic hypertrophy: update -nonsystematic review
2013	HAYES, Inc.	Transradial, transbrachial, and transulnar approaches for coronary angiography and intervention
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Transradial access for cardiac catheterization
2002	HAYES, Inc.	Transpupillary thermotherapy for choroidal tumors and macular degeneration
2004	National Institute for Health and Care Excellence (NICE)	Transpupillary thermotherapy for age-related macular degeneration. NICE interventional procedures guidance 58
2002	NIHR Horizon Scanning Centre (NIHR HSC)	Transpupillary thermotherapy for age-related macular degeneration - horizon scanning review
2003	Institute for Clinical Effectiveness and Health Policy (IECS)	Transpupillary thermotherapy
2007	New Zealand Health Technology Assessment (NZHTA)	Transportation of emergency patients
2012	NIHR Horizon Scanning Centre (NIHR HSC)	Transportable haemodialysis machines for established renal failure
2002	Blue Cross Blue Shield Association (BCBS)	Transplanting adult patients with hematopoietic stem cells from placental and umbilical cord blood
1994	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Transplantation with bone marrow not derived from HLA identical family donors for the treatment of adults and children with hemato-oncologic and congenital diseases - primary research
2001	The Swedish Council on Health Technology Assessment (SBU)	Transplantation of stem cells from umbilical cord blood - early assessment briefs (Alert)
2003	The Swedish Council on Health Technology Assessment (SBU)	Transplantation of cultured skin (Apligraf(R)) in treating venous leg ulcers - early assessment briefs (Alert)
2005	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Transplantation of allogeneic hematopoietic stem cells from unrelated donors in adult patients at the MUHC
2002	HAYES, Inc.	Transperineal ultrasound-guided brachytherapy for early-stage prostate cancer
2010	National Institute for Health and Care Excellence (NICE)	Transperineal template biopsy and mapping of the prostate. NICE interventional procedures guidance 364
2025	National Institute for Health and Care Excellence (NICE)	Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE interventional procedures guidance 798
2022	Norwegian Institute of Public Health (NIPH)	Transperineal compared with transrectal biopsy on suspected prostate cancer: a health technology assessment
2023	National Institute for Health and Care Excellence (NICE)	Transperineal biopsy for diagnosing prostate cancer. NICE diagnostics guidance 54
2024	NIHR Health Technology Assessment programme	Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transoral robotic surgery: a review of clinical and cost-effectiveness
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Transoral endoscopic thyroidectomy vestibular approach (TOETVA)
2014	National Institute for Health and Care Excellence (NICE)	Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. NICE interventional procedures guidance 484
2002	Medical Services Advisory Committee (MSAC)	Transoesophageal echocardiography
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transobturator slings for urinary incontinence: clinical effectiveness and guidelines
1998	Institute of Technology Assessment (ITA)	Transnational analysis of the socio-economic impact of Alzheimer's disease (AD) in the European Union
2011	Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS)	Transnasal oesophagoscopy (TNE)
1996	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Transmyocardial revascularization with laser
2002	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Transmyocardial revascularization for treatment of angina
1998	University HealthSystem Consortium (UHC)	Transmyocardial revascularization
1998	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Transmyocardial revascularisation by laser (systematic review, expert panel)
2000	Institute for Clinical Systems Improvement (ICSI)	Transmyocardial laser therapy for severe refractory angina
2002	HAYES, Inc.	Transmyocardial laser revascularization
2009	National Institute for Health and Care Excellence (NICE)	Transmyocardial laser revascularisation for refractory angina pectoris. NICE interventional procedures guidance 301
1999	Medical Services Advisory Committee (MSAC)	Transmyocardial laser revascularisation
2019	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Transmural fixation of aortic endograft adjunct to endovascular aneurysm repair using helical anchors
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Transmission of respiratory infections via showers
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transmission of infectious agents from magazines, books, and toys in healthcare settings: clinical evidence and guidelines
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Transmission of infectious agents and risk of injury from patient transfer boards in healthcare settings: clinical evidence
2003	L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES)	Transluminal dilatation for symptomatic atheromatous stenosis of the carotid bifurcation
1995	NIHR Health Technology Assessment programme	Translation of Spanish report on routine pre-operative testing
2015	NIHR Health Services and Delivery Research programme	Translation into British Sign Language and validation of the Strengths and Difficulties Questionnaire
2013	National Institute for Health and Care Excellence (NICE)	Translaryngeal tracheostomy. NICE interventional procedures guidance 462
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Transjugular Intrahepatic Portosystemic Shunts for Patients with Acute Variceal Bleeding
1996	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Transjugular intrahepatic porto-systemic shunt - systematic review, expert panel, primary research